It has been observed that BRAF inhibitor-resistant melanomas display increased reliance on glutamine and activate the NRF2 pathway, increasing xCT expression and GSH levels to evade ferroptosis (Khamari et al., 2018). This evidence concerns the gene SLC7A11 and melanoma.